Amicus Therapeutics Inc Revenue Growth Rates (FOLD), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Amicus Therapeutics inc   (NASDAQ: FOLD)
 

FOLD's Revenue Growth by Quarter and Year

Amicus Therapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

FOLD Revenue (in millions $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter December 185.21
3rd Quarter September 168.59
2nd Quarter June 154.47
1st Quarter March 124.55
FY 632.82

FOLDs Annual Revenue
Amicus Therapeutics Inc 's Revenue in the fiscal year 2025 $ 633.28 millions
Amicus Therapeutics Inc 's Revenue in the fiscal year 2024 $ 527.35 millions
Amicus Therapeutics Inc 's Revenue in the fiscal year 2023 $ 399.03 millions
Amicus Therapeutics Inc 's Revenue in the fiscal year 2022 $ 329.23 millions
Amicus Therapeutics Inc 's Revenue in the fiscal year 2021 $ 305.51 millions




FOLD Revenue fourth quarter 2025 Y/Y Growth Comment
Amicus Therapeutics inc reported Revenue improvement of 23.71% year on year in the fourth quarter 2025, to $ 185.21 millions, this is lower than Amicus Therapeutics Inc 's recent average Revenue rise of 58.13%.

Looking into fourth quarter 2025 results within Major Pharmaceutical Preparations industry 19 other companies have achieved higher Revenue growth. While Amicus Therapeutics Inc ' s Revenue rise of 23.71% ranks overall at the positon no. 606 in the fourth quarter 2025.


FOLD Revenue ( Y/Y Growth %) 2025
 2024 2023 2022
4th Quarter December 23.71 % 30.09 % 30.62 % 7.24 %
3rd Quarter September 19.36 % 37.71 % 25.55 % 2.69 %
2nd Quarter June 22.2 % 33.92 % 16.92 % 4.29 %
1st Quarter March 13.39 % 27.32 % 9.59 % 18.55 %
FY   20.03 % 32.36 % 20.98 % -

Financial Statements
Amicus Therapeutics Inc 's fourth quarter 2025 Revenue $ 185.21 millions FOLD's Income Statement
Amicus Therapeutics Inc 's fourth quarter 2024 Revenue $ 149.71 millions Quarterly FOLD's Income Statement


FOLD Revenue (Quarter on Quarter Growth %)

 2025
 2024 2023 2022
4th Quarter December 9.86 % 6 % 12.21 % 7.85 %
3rd Quarter September 9.14 % 11.73 % 8.66 % 1.19 %
2nd Quarter June 24.02 % 15.09 % 9.41 % 2.55 %
1st Quarter March -16.81 % -4.55 % -2.08 % -4.18 %
FY (Year on Year)   20.03 % 32.36 % 20.98 % -


Back to FOLD Growth rate Comparisons >> Back to FOLD Growth rate Comparisons >>


Revenue fourth quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #20
Healthcare Sector #78
Overall #606

Revenue Y/Y Growth Statistics
High Average Low
290.59 % 58.13 % 5.97 %
(Jun 30 2018)   (Mar 31 2023)
Revenue fourth quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #20
Healthcare Sector #78
Overall #606
Revenue Y/Y Growth Statistics
High Average Low
290.59 % 58.13 % 5.97 %
(Jun 30 2018)   (Mar 31 2023)

Revenue by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

Amicus Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
730.77 % 26.91 % -100 %
(Dec 31 2013)  


FOLD's IV. Quarter Q/Q Revenue Comment
Amicus Therapeutics inc achieved in the IV. Quarter 2025 below company average Revenue increase of 9.86% quarter on quarter, to $ 185.21 millions.

Although the IV. Quarter 2025 Revenue Q/Q growth was lower than the regular , this has been yet encouraging story, as the IV. Quarter surge, eclipses the 6% growth in the IV. Quarter a year ago

Within Major Pharmaceutical Preparations industry 13 other companies have achieved higher Revenue quarter on quarter growth. While Amicus Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 299.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #14
Healthcare Sector #44
Overall #299
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #14
Healthcare Sector #44
Overall #299
Revenue Q/Q Growth Statistics
High Average Low
730.77 % 26.91 % -100 %
(Dec 31 2013)  


FOLD's IV. Quarter Q/Q Revenue Comment
Amicus Therapeutics inc achieved in the IV. Quarter 2025 below company average Revenue increase of 9.86% quarter on quarter, to $ 185.21 millions.

IV. Quarter 2025 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 6% in the IV. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 13 other companies have achieved higher Revenue quarter on quarter growth. While Amicus Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 299.


Amicus Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)		 12 Months Ending
(Mar 31 2025)		 12 Months Ending
(Dec 31 2024)
Cumulative Revenue 12 Months Ending $ 632.83 $ 597.32 $ 569.97 $ 541.90 $ 527.19
Y / Y Revenue Growth (TTM) 20.04 % 21.27 % 25.58 % 28.46 % 32.36 %
Year on Year Revenue Growth Overall Ranking # 109 # 199 # 363 # 460 # 185
Seqeuential Revenue Change (TTM) 5.94 % 4.8 % 5.18 % 2.79 % 7.03 %
Seq. Revenue Growth (TTM) Overall Ranking # 606 # 837 # 350 # 1482 # 544


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Dec 31 2025 period, Amicus Therapeutics Inc 's cumulative twelve months Revenue were $ 633 millions, company would post below average annual Revenue growth of 7.03% year on year, if the fiscal year would end at Dec 31 2025.
A slow-down in the Amicus Therapeutics Inc 's Revenue growth from the 168.59% growth in Sep 30 2025.

Within the Healthcare sector 23 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 109, from total ranking in previous quarter at 199.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 20
Healthcare Sector # 24
Overall # 109

Revenue TTM Y/Y Growth Statistics
High Average Low
290.59 %
 58.13 %
5.97 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 20
Sector # 78
S&P 500 # 606
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Dec 31 2025 period, Amicus Therapeutics Inc 's cumulative twelve months Revenue were $ 633 millions, company would post below average annual Revenue growth of 5.97% year on year, if the fiscal year would end at Dec 31 2025.
A slow-down in the Amicus Therapeutics Inc 's Revenue growth from the 168.59% growth in Sep 30 2025.

Within the Healthcare sector 23 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 109, from total ranking in previous quarter at 199.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 20
Healthcare Sector # 24
Overall # 109

Revenue TTM Y/Y Growth Statistics
High Average Low
290.59 %
58.13 %
5.97 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 20
Sector # 78
S&P 500 # 606




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
FOLD's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue increase for the quarter ending Dec 31 2025 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2025
Vystar Corporation41.19%$ 41.186 millions
Prelude Therapeutics Inc41.00%$ 41.000 millions
Biodesix Inc 40.76%$ 40.756 millions
Ligand Pharmaceuticals Incorporated40.01%$ 40.008 millions
Femasys Inc 39.84%$ 39.844 millions
Natera Inc 39.79%$ 39.793 millions
Guardant Health Inc 39.37%$ 39.369 millions
Innovative Eyewear Inc 38.96%$ 38.964 millions
Ceribell Inc 38.36%$ 38.357 millions
Gsk Plc37.35%$ 37.347 millions
Rapid Micro Biosystems Inc 37.28%$ 37.284 millions
Nexgel Inc 36.92%$ 36.918 millions
Rhythm Pharmaceuticals Inc 36.87%$ 36.871 millions
Adc Therapeutics Sa36.36%$ 36.357 millions
Logicmark Inc36.29%$ 36.290 millions
Biofrontera Inc 36.16%$ 36.157 millions
Butterfly Network Inc 35.74%$ 35.743 millions
Evofem Biosciences Inc 34.59%$ 34.586 millions
Clearpoint Neuro Inc 33.96%$ 33.960 millions
Therapeuticsmd Inc 33.88%$ 33.883 millions
Apyx Medical Corp33.65%$ 33.647 millions
Gyre Therapeutics Inc 33.45%$ 33.449 millions
Harrow Inc 33.31%$ 33.309 millions
Delcath Systems Inc 33.28%$ 33.282 millions
Beone Medicines Ltd 32.84%$ 32.837 millions
Veracyte Inc 32.81%$ 32.815 millions
Transmedics Group Inc 32.18%$ 32.181 millions
Medpace Holdings Inc 32.03%$ 32.028 millions
Quipt Home Medical Corp 31.96%$ 31.956 millions
Immutep Limited31.80%$ 31.801 millions


About Amicus Therapeutics Inc Revenue Growth Rates (FOLD), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Amicus Therapeutics Inc (CIK 1178879).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001178879-26-000005
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Amicus Therapeutics Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.